Oct. 17 - The ‘national priority’ voucher winners, two more China deals and I-Mab’s transformation
I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy; Drugs from China are reshaping biotech. Track the licensing deals here.; A longshot bet on a tremor drug pays off
Join the world’s largest labor and employment law firm to learn how to guard against unfair competition & protect talent and trade secrets.
Register: Littler Webinar.
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine were among the first beneficiaries of a pilot program initiated in June.
I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.
Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive data from a pair of late-stage clinical trials.
